Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
04/2003
04/29/2003US6555548 Administering therapeutically effective amount of active agent selected from the group consisting of a heterocyclic amine-type compound, a substituted phenylazacycloalkane-type compound, and a cabergoline-type compound, and their salts
04/29/2003US6555542 Sulfonamide lactam inhibitors of FXa and method
04/29/2003US6555377 Process for production of mammalian cell lines
04/24/2003WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/24/2003WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
04/24/2003WO2003033481A1 Benzoxazine and benzothiazine derivatives and parmaceutical compositions containing them
04/24/2003WO2003033470A1 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
04/24/2003WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors
04/24/2003WO2003033456A1 NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS
04/24/2003WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases
04/24/2003WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
04/24/2003WO2003032921A2 Treatment of neurodegenerative diseases and cancer of the brain
04/24/2003WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
04/24/2003WO2003032912A2 Treatment of cns disorders using cns target modulators
04/24/2003WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction
04/24/2003WO2003032897A2 Azabicyclic compounds for the treatment of fibromyalgia syndrome
04/24/2003WO2003032753A1 Use of cystathionine
04/24/2003WO2003032735A1 Remodeling of tissues and organs
04/24/2003WO2002098850A3 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
04/24/2003WO2002072822A3 Als2 gene and amyotrophic lateral sclerosis type 2
04/24/2003WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
04/24/2003WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors
04/24/2003WO2002046383A3 Protein modification and maintenance molecules
04/24/2003WO2002026825A3 G-protein coupled receptors
04/24/2003US20030078276 Matrix metalloproteinase inhibitors
04/24/2003US20030078275 For therapy of cancer, diabetes and Alzheimer's disease
04/24/2003US20030078265 Inhibitors of nitric oxide synthase (nos)
04/24/2003US20030078252 Used to treat abnormal cell growth and central nervous system disorders
04/24/2003US20030078236 Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain
04/24/2003US20030078235 Treatment of central nervous system disorders; anticonvulsants, antiepileptics, neuroprotective agents and muscle relaxants
04/24/2003US20030078212 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
04/24/2003US20030077802 Human PRL1 phosphatase
04/24/2003US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor
04/24/2003US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
04/24/2003US20030077280 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated T cells and thereby inhibits T cell activation of B cells
04/24/2003US20030077246 TNFr/OPG-like molecules and uses thereof
04/24/2003CA2727642A1 Synthesis of cyclosporin analogs
04/24/2003CA2463850A1 Remodeling of tissues and organs
04/24/2003CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors
04/24/2003CA2463686A1 Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
04/24/2003CA2463685A1 Novel .beta.-phenyl-.alpha.-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
04/24/2003CA2463579A1 Treatment of cns disorders using cns target modulators
04/24/2003CA2463518A1 Carbinols for the treatment of neuropathic dysfunction
04/24/2003CA2462147A1 Bicyclic oxopyridine and oxopyrimidine derivatives
04/24/2003CA2461758A1 Use of cystathionine
04/24/2003CA2460685A1 Cyclosporine analogue mixtures and their use as immunomodulating agents
04/23/2003EP1303607A2 High affinity soluble interleukin-18 receptor
04/23/2003EP1303536A1 Novel fibroblast growth factor (fgf23) and methods for use
04/23/2003EP1303521A1 Tetrahydro-heterocycloazepinyl pyrimidine derivatives
04/23/2003EP1303517A1 Indoloquinazolinones
04/23/2003EP1303501A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
04/23/2003EP1303499A1 Tetrazole derivatives
04/23/2003EP1303296A1 Composition containing an iron complexing protein and a precursor of nitrogen monoxide metabolism and/or a chemical donor of nitrogen monoxide and uses thereof
04/23/2003EP1303272A2 Benzothiazole derivatives
04/23/2003EP1107744B1 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia
04/23/2003EP0993442B1 Hydrazine derivatives
04/23/2003EP0937041B1 Use of a pharmaceutically acceptable salt of (3R,2'R)-3-[(Cyclopently-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
04/23/2003EP0893951A4 METHODS OF MODULATING RADICAL FORMATION BY MUTANT CuZnSOD ENZYMES
04/23/2003CN1413250A Method of producing differentiated progenitor cells and lineage-defective embryonic stem cells
04/23/2003CN1413207A 5-membered ring heterocyclic compounds with nitrogen
04/23/2003CN1413105A Novel method of treatment
04/23/2003CN1413104A New (aminopropyl) methylphosphinic acids
04/23/2003CN1411811A 血液循环改善剂 Blood circulation improving agent
04/23/2003CN1106379C 2-propyl valeramide and 2-propyl valeramide derivative and medical use as anticonvulsants
04/22/2003US6552168 Inhibition of apoptosis via attenuation of caspase activity should therefore be useful in the treatment of human diseases where inappropriate apoptosis is prominent or contributes to disease pathogenesis
04/22/2003US6552075 Therapeutic compounds and methods of use
04/22/2003US6552041 Cyclized amide derivatives useful for treating or preventing neuronal damage associated with neurological disease
04/22/2003US6552019 Inhibitors of p38
04/22/2003US6552003 Muscle reinnervation and motor axon sprouting by administering DNA sequences encoding NT-3 and CNTF
04/22/2003US6551810 Polypeptide retains the ability to dephosphorylate an activated MAP-kinase
04/22/2003US6551626 Composition containing pyrrolizidine-alkaloid-free petasites
04/22/2003CA2253869C Substituted oxobutyric acids as matrix metalloprotease inhibitors
04/17/2003WO2003031940A2 Structural and cytoskeleton-associated proteins
04/17/2003WO2003031939A2 Protein modification and maintenance molecules
04/17/2003WO2003031440A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003WO2003031422A1 Novel benzothiazine derivatives, their preparation and use
04/17/2003WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
04/17/2003WO2003030944A2 Inhibition of stat-1
04/17/2003WO2003030920A1 An antispasmodic agent spaced drug delivery system
04/17/2003WO2003030912A1 Prostaglandin analogs as chloride channel opener
04/17/2003WO2003030905A1 Dihydroorotate dehydrogenase inhibitor
04/17/2003WO2003030904A1 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
04/17/2003WO2003030897A1 Pyrrolidinone derivatives
04/17/2003WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003WO2003030875A1 Over-coated chewing gum formulations including tableted center
04/17/2003WO2003030823A2 Combinations for the treatment of immunoinflammatory disorders
04/17/2003WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor
04/17/2003WO2003007887A3 Substituted imidazoles as cannabinoid receptor modulators
04/17/2003WO2002079221A3 Sapogenin derivatives, their synthesis and use
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002018575A3 Genes expressed in the cell cycle
04/17/2003WO2001072752A3 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS
04/17/2003US20030073727 Central nervous system disorders
04/17/2003US20030073726 Heterocyclic inhibitors of glycine transporter 2
1 ... 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 ... 233